Published in BMC Infect Dis on May 04, 2013
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 1.71
Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment. PLoS One (2016) 1.39
Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity (2014) 1.28
Novel roles for the polyphenol oxidase enzyme in secondary metabolism and the regulation of cell death in walnut. Plant Physiol (2014) 1.04
Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS (2014) 0.90
Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retroviruses (2014) 0.88
Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J Neuroimmune Pharmacol (2013) 0.88
Role of endoplasmic reticulum stress in drug-induced toxicity. Pharmacol Res Perspect (2016) 0.86
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. PLoS One (2014) 0.83
Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS (2015) 0.83
Chronic binge alcohol consumption does not diminish effectiveness of continuous antiretroviral suppression of viral load in simian immunodeficiency virus-infected macaques. Alcohol Clin Exp Res (2014) 0.83
Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin North Am (2014) 0.81
Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. PLoS One (2014) 0.79
ASPP2 attenuates triglycerides to protect against hepatocyte injury by reducing autophagy in a cell and mouse model of non-alcoholic fatty liver disease. J Cell Mol Med (2014) 0.79
Acylcarnitine Profiles in HIV-Exposed, Uninfected Neonates in the United States. AIDS Res Hum Retroviruses (2016) 0.78
Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep (2015) 0.78
Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals. EBioMedicine (2016) 0.77
HIV protease inhibitors in gut barrier dysfunction and liver injury. Curr Opin Pharmacol (2014) 0.77
Mid-ATR-FTIR spectroscopic profiling of HIV/AIDS sera for novel systems diagnostics in global health. OMICS (2014) 0.77
Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions. Biol Open (2016) 0.76
1H Nuclear Magnetic Resonance Metabolomics of Plasma Unveils Liver Dysfunction in Dengue Patients. J Virol (2016) 0.75
Plasma sphingolipids in HIV-associated chronic obstructive pulmonary disease. BMJ Open Respir Res (2017) 0.75
A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C. Clin Transl Med (2016) 0.75
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study. Medicine (Baltimore) (2016) 0.75
Global Metabolomic Analysis of a Mammalian Host Infected with Bacillus anthracis. Infect Immun (2015) 0.75
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Inflammation, stress, and diabetes. J Clin Invest (2005) 17.11
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab (2008) 9.74
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology (1999) 4.14
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature (2008) 3.94
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
HIV disease and the endocrine system. N Engl J Med (1992) 3.48
Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell (2003) 2.99
Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med (1993) 2.96
Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med (1992) 2.59
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol (2004) 2.47
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 2.43
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet (2010) 2.34
Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem (2009) 2.28
Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol (1987) 2.28
Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician (2004) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res (2000) 2.18
HIV infection and the risk of diabetes mellitus. AIDS (2009) 2.10
Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr (2005) 2.07
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis (2008) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis (2006) 2.01
Increasing burden of liver disease in patients with HIV infection. Lancet (2011) 1.98
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol (1992) 1.83
Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol (2008) 1.82
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) (2010) 1.73
Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol (2011) 1.56
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest (1994) 1.53
Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest (1993) 1.46
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS (2003) 1.43
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis (2004) 1.43
Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology. N Engl J Med (1974) 1.42
Management of hepatic complications in HIV-infected persons. J Infect Dis (2008) 1.42
Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab (1998) 1.40
Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest (1994) 1.39
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol (1993) 1.37
Nuclear receptors in liver disease. Hepatology (2011) 1.34
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res (2010) 1.29
Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. PLoS One (2012) 1.27
The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis (2003) 1.25
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol (2002) 1.21
Dehydroepiandrosterone (DHEA)--a precursor steroid or an active hormone in human physiology. J Sex Med (2011) 1.16
Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology (1994) 1.15
Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis (2003) 1.15
HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis (2007) 1.14
Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS (2006) 1.13
Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol (2000) 1.10
Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.10
Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther (2008) 1.10
Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res (1993) 1.07
Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci (2000) 1.06
A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol (2008) 1.05
Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS One (2011) 1.03
Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog (2010) 1.00
Omega-3 and omega-6 fatty acids suppress ER- and oxidative stress in cultured neurons and neuronal progenitor cells from mice lacking PPT1. Neurosci Lett (2010) 0.98
Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol (2011) 0.97
Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr Opin Infect Dis (2012) 0.96
Interleukin 6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis (1992) 0.95
Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci (2011) 0.92
Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials (2002) 0.92
Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology (1994) 0.92
Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol (2008) 0.91
Prognostic significance of serum bile acids in cirrhosis. Hepatology (1986) 0.90
The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2010) 0.88
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. J Viral Hepat (2012) 0.88
From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis (2012) 0.86
YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol (2011) 0.84
Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS (2007) 0.84
Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS (2000) 0.82
Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy (2010) 0.82
Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. Nutrition (1997) 0.81
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) (2000) 0.79
The human plasma lipidome. N Engl J Med (2012) 0.78
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS One (2010) 0.77
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev (2004) 3.28
Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med (2003) 3.02
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol (2002) 2.44
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A (2006) 2.13
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem (2006) 2.06
NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol Cell Biol (2007) 1.86
Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics (2009) 1.86
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis (2007) 1.79
JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol (2005) 1.79
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol (2007) 1.73
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol (2008) 1.60
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr (2011) 1.52
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal (2010) 1.50
Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (2012) 1.44
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology (2007) 1.43
Pathogenesis of macrophage tropic HIV-1. Curr HIV Res (2005) 1.43
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Cigarette smoke-induced emphysema in A/J mice is associated with pulmonary oxidative stress, apoptosis of lung cells, and global alterations in gene expression. Am J Physiol Lung Cell Mol Physiol (2009) 1.40
Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol (2004) 1.38
Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol (2008) 1.37
Urinary NGAL marks cystic disease in HIV-associated nephropathy. J Am Soc Nephrol (2009) 1.34
Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. Arch Biochem Biophys (2006) 1.33
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Mechanisms of HIV-1 neurotropism. Curr HIV Res (2006) 1.33
The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int (2008) 1.33
Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J Virol (2005) 1.31
Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. Am J Pathol (2004) 1.28
A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One (2012) 1.27
CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol (2006) 1.27
The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One (2012) 1.27
Quality of life in HIV subtype C infection among asymptomatic subjects and its association with CD4 counts and viral loads--a study from South India. Qual Life Res (2006) 1.25
JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol (2011) 1.25
Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol (2004) 1.23
CD16+ monocytes exposed to HIV promote highly efficient viral replication upon differentiation into macrophages and interaction with T cells. Virology (2005) 1.22
Cocaine hijacks σ1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS. J Neurosci (2011) 1.21
Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr (2013) 1.21
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis (2008) 1.18
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol (2009) 1.17
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr (2011) 1.16
Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog (2011) 1.14
CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. J Immunol (2006) 1.14
Movement disorders and AIDS: a review. Parkinsonism Relat Disord (2004) 1.12
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Ante mortem diagnosis of human rabies using saliva samples: comparison of real time and conventional RT-PCR techniques. J Clin Virol (2006) 1.11
Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet (2002) 1.10
Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol (2013) 1.10
A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2. J Virol (2006) 1.10
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS (2012) 1.09
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology (2007) 1.09
Segmentation of Brain Immunohistochemistry Images Using Clustering of Linear Centroids and Regional Shapes. J Imaging Sci Technol (2008) 1.09
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol (2008) 1.08
Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Infect Dis (2002) 1.07
Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology (2004) 1.07
Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res (2012) 1.07
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology (2008) 1.07
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
Lifetime suicidal ideation and attempt are common among HIV+ individuals. J Affect Disord (2011) 1.06
Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role for exocyst complex proteins in mediating enhancement of intercellular nanotube formation. Retrovirology (2012) 1.05
HIV-1-infected and/or immune-activated macrophages regulate astrocyte CXCL8 production through IL-1beta and TNF-alpha: involvement of mitogen-activated protein kinases and protein kinase R. J Neuroimmunol (2008) 1.04
Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. Retrovirology (2009) 1.03
Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell Mol Biol (2010) 1.02
Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol (2004) 1.02
Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol (2003) 1.01
Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res Hum Retroviruses (2008) 1.00
An "Omics" based survey of human colon cancer. Mutat Res (2010) 1.00
Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. PLoS One (2013) 0.99
Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection. Curr HIV Res (2014) 0.98
Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol (2004) 0.98
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98